Top

Published in:

01-04-2010 | Short Communication

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells

Authors: Zoran Popmihajlov, Fabio R. Santori, Daniel Gebreselassie, Anthony D. Sandler, Stanislav Vukmanovic

Published in: Cancer Immunology, Immunotherapy | Issue 4/2010

Abstract

High avidity for antigen and diversity of T cell receptor (TCR) repertoire are essential for effective immunity against cancer. We have previously created a transgenic mouse strain with increased TCR avidity in a diverse T cell population. In this report, we show that strong alloreactive responses of transgenic T cells against targets with low MHC class I expression can be used for effective adoptive transfer of tumor immunity in vivo. Alloreactive transgenic T cells could be an effective therapeutic approach counteracting tumor evasion of the immune system.

Rosenberg SA et al (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308CrossRefPubMed

Schumacher TN, Restifo NP (2009) Adoptive T cell therapy of cancer. Curr Opin Immunol 21(2):187–189CrossRefPubMed

Zeh HJI et al (1999) High avidity CTLs for two self antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989–994PubMed

Van den Eynde BJ, Boon T (1997) Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27(2):81–86CrossRefPubMed

Bouneaud C, Kourilsky P, Bousso P (2000) Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829–840CrossRefPubMed

Stauss HJ (1999) Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 20:180–183CrossRefPubMed

Stauss HJ et al (2004) Exploiting alloreactivity for tumour immunotherapy. Vox Sang 87(Suppl 2):227–229CrossRefPubMed

Kolb HJ (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112(12):4371–4383CrossRefPubMed

Childs R et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343(11):750–758CrossRefPubMed

10.

Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3(11):999–1005CrossRefPubMed

11.

Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227–236CrossRefPubMed

12.

Garcia-Lora A et al (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 106(4):521–527CrossRefPubMed

13.

Vago L et al (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361(5):478–488CrossRefPubMed

14.

van Hall T et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12(4):417–424CrossRefPubMed

15.

Santori FR et al (2007) TCRβ chain that forms peptide-independent alloreactive TCR transfers reduced reactivity with irrelevant peptide/MHC complex. J Immunol 178:6109–6114PubMed

16.

Stojakovic M et al (2008) Adaptable TCR avidity thresholds for negative selection. J Immunol 181:6770–6778PubMed

17.

Nesic D et al (2002) Factors influencing the patterns of T lymphocyte allorecognition. Transplantation 73:797–803CrossRefPubMed

18.

Gebreselassie D, Spiegel H, Vukmanovic S (2006) Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 67:894–906CrossRefPubMed

19.

Balendiran GK et al (1997) The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide. Proc Natl Acad Sci USA 94(13):6880–6885CrossRefPubMed

20.

Udaka K et al (1993) A ubiquitous protein is the source of naturally occurring peptides that are recognized by a CD8⁺ T-cell clone. Proc Natl Acad Sci USA 90:11272–11276CrossRefPubMed

21.

Uenaka A et al (1994) Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 180:1599–1607CrossRefPubMed

22.

Sabatino DE et al (2005) Identification of mouse AAV capsid-specific CD8 + T cell epitopes. Mol Ther 12(6):1023–1033CrossRefPubMed

23.

Kearney ER et al (1994) Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1(4):327–339CrossRefPubMed

24.

Kruger T et al (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol Immunother 54:826–836CrossRefPubMed

25.

Sandberg JK, Karre K, Glas R (1999) Recognition of the major histocompatibility complex restriction element modulates CD8⁺ T cell specificity and compensates for loss of T cell receptor contacts with the specific peptide. J Exp Med 189:883–893CrossRefPubMed

Title: Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells
Authors: Zoran Popmihajlov
Fabio R. Santori
Daniel Gebreselassie
Anthony D. Sandler
Stanislav Vukmanovic
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 4/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-009-0805-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I–III melanoma patients

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties

Erratum to: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo

Regulation of immunity and oncogenesis by the IRF transcription factor family

Keynote webinar | Spotlight on antibody–drug conjugates in cancer